EGFR and non-small cell lung carcinoma: The combination strategy of EGFR–TKI and anlotinib exhibited superior treatment effects and negligible adverse events in advanced EGFR‐mutant NSCLC patients after EGFR‐TKI resistance, especially in patients experiencing gradual progression.